The BRAFV600E mutation occurs in 50–60% of melanomas [4,5], and small molecule kinase inhibitors targeting BRAF and MEK have become the standard treatment for patients with inoperable BRAFV600E melanoma [6,7]. This evidence concerns the gene MAP2K7 and melanoma.